Question explored with the scientific record
Conversation so far
- 1 I’m 40 with chronic kidney disease. What can I do to extend my life expectancy?
- 2 I’m 40 with chronic kidney disease. What can I do to extend my life expectancy?
Answered on this page ↓
I’m 40 with chronic kidney disease. What can I do to extend my life expectancy?
The short version: the previous answer's numbers were not all from the records in front of me, and I should have said so.
I overstated. The perindopril "30% reduction, 11 treated to prevent one event" figure and the "RAAS blockade reduced dialysis or death" claim were not in the studies I was given. I cannot confirm them here. What the records actually show is narrower and partly contradictory.
The strongest hard-outcome evidence is blood pressure. A meta-analysis of 18 trials in CKD stages 3 to 5 found more intensive lowering cut all-cause death, 7.8% versus 8.4% [1]. A separate analysis found a systolic target under 120 reduced death, 70 versus 95 events [2]. But a 2013 review found lower targets cut kidney failure only in people with protein in the urine, a 27% relative reduction, and not in those without [4]. A Korean cohort put the risk threshold at 135 mm Hg for reduced kidney function and 125 mm Hg with proteinuria [5].
| Finding | What the records show |
|---|---|
| All-cause death, intensive BP | 7.8% vs 8.4% [1] |
| All-cause death, target under 120 | 70 vs 95 events [2] |
| Kidney failure, lower target, proteinuria | 27% relative reduction [4] |
| Kidney failure, lower target, no proteinuria | No benefit [4] |
| Death threshold, reduced kidney function | 135 mm Hg [5] |
RAAS blockers are not the clean win I implied. In non-proteinuric CKD they did not reduce cardio-renal events or death [3]. In proteinuric CKD they do reduce protein and slow decline [6]. The distinction is protein, not the drug class.
My call: get your urine protein number first, then push blood pressure hard if it is elevated, and treat RAAS blockade as conditional on proteinuria rather than automatic. Confidence: moderate.
Sources used 6
-
Association Between More Intensive vs Less Intensive Blood Pressure Lowering and Risk of Mortality in Chronic Kidney Disease Stages 3 to 5
This systematic review and meta-analysis of 18 randomized clinical trials involving 15,924 patients with chronic kidney disease stages 3 to 5 found that more intensive blood pressure lowering is associated with a significantly lower risk of all-cause mortality compared to less i…
DOI: 10.1001/jamainternmed.2017.4377 -
Effects of Intensive BP Control in CKD
This study investigates the effects of intensive blood pressure control on cardiovascular and kidney outcomes in patients with chronic kidney disease (CKD) and hypertension, finding that targeting a systolic blood pressure of less than 120 mm Hg significantly reduces rates of ma…
DOI: 10.1681/ASN.2017020148 -
Renin-angiotensin system inhibitor use and cardio-renal outcomes in non-proteinuric chronic kidney disease: a post-hoc analysis of the Frontier of Renal Outcome Modification-Japan study
Renin-angiotensin system inhibitors did not reduce long-term cardio-renal events or mortality in Japanese patients with non-proteinuric chronic kidney disease.
DOI: 10.1038/s41440-025-02536-x -
Blood pressure targets in chronic kidney disease: Does proteinuria dictate how low we go?
This commentary discusses the implications of a systematic review on blood pressure targets in chronic kidney disease, highlighting the potential benefits of lower targets in patients with proteinuria while noting the limitations of the evidence supporting these guidelines.
DOI: 10.1503/cmaj.130168 -
On-treatment blood pressure and long-term outcomes in chronic kidney disease
In Korean CKD antihypertensive users, composite cardiovascular, kidney failure, and mortality risk rose above systolic BP 135 mm Hg with reduced eGFR and 125 mm Hg with proteinuria; proteinuric CKD showed greater intensive-lowering benefit than non-CKD.
DOI: 10.1093/ndt/gfab151 -
Proteinuria in Chronic Kidney Disease and its Management
ACE inhibitors and ARBs reduce proteinuria and slow CKD progression (including DKD); they should be used in CKD patients with significant proteinuria, and microalbuminuria may regress with treatment.
DOI: 10.3329/medtoday.v25i1.16070